Free Trial
→ Collect $7k per month from Tesla’s SECRET dividend (From Investors Alley) (Ad)

Indivior Q4 2024 Earnings Report

Indivior logo
$8.46 -0.53 (-5.84%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Indivior EPS Results

Actual EPS
$0.32
Consensus EPS
$0.32
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Indivior Revenue Results

Actual Revenue
$298.00 million
Expected Revenue
$262.35 million
Beat/Miss
Beat by +$35.65 million
YoY Revenue Growth
N/A

Indivior Announcement Details

Quarter
Q4 2024
Date
2/20/2025
Time
Before Market Opens

Conference Call Resources

Indivior Earnings Headlines

Indivior price target lowered to $15 from $16 at Craig-Hallum
February 21 at 1:24 PM | markets.businessinsider.com
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans
February 20 at 4:06 PM | seekingalpha.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
Indivior price target lowered to 1,100 GBp from 1,400 GBp at Stifel
February 20 at 4:06 PM | markets.businessinsider.com
Indivior PLC 2024 Q4 - Results - Earnings Call Presentation
February 20 at 9:46 AM | seekingalpha.com
Indivior weakness on delay a buying opportunity, says Northland
February 13, 2025 | markets.businessinsider.com
See More Indivior Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indivior? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indivior and other key companies, straight to your email.

About Indivior

Indivior (NASDAQ:INDV), together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

View Indivior Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles